Clinical actionability of molecular targets in endometrial cancer

Urick, Mary Ellen; Bell, Daphne W.

doi:10.1038/s41568-019-0177-x

Cited by 411Endometrial and Cervical Cancer TreatmentsBreast Cancer Treatment StudiesOvarian cancer diagnosis and treatment

Clinical actionability of molecular targets in endometrial cancer

Open access

Urick, Mary Ellen, Bell, Daphne W.·2019·Nature Reviews Cancer

DOI 10.1038/s41568-019-0177-xPMC PMC7446243

Open this paper in CoChat — free account

Abstract

Endometrial cancer accounts for ~76,000 deaths among women each year worldwide. Disease mortality and the increasing number of new diagnoses make endometrial cancer an important consideration in women's health, particularly in industrialized countries, where the incidence of this tumour type is highest. Most endometrial cancers are carcinomas, with the remainder being sarcomas. Endometrial carcinomas can be classified into several histological subtypes, including endometrioid, serous and clear cell carcinomas. Histological subtyping is currently used routinely to guide prognosis and treatment decisions for endometrial cancer patients, while ongoing studies are evaluating the potential clinical utility of molecular subtyping. In this Review, we summarize the overarching molecular features of endometrial cancers and highlight recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41568-019-0177-x

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The combined presence of PTEN and PIK3CA or PIK3R1 mutations are frequently observed suggesting that both loss of tumor suppressor and activation of oncogenes is required during tumor progression.
“the combined presence of PTEN and PIK3CA or PIK3R1 mutations are frequently observed suggesting that both loss of tumor suppressor and activation of oncogenes is required during tumor progression53.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [53]
The 'Endometrioid endometrial cancer' section (page not provided) says PTEN mutations commonly co-occur with PIK3CA and PIK3R1 mutations in human endometrioid endometrial cancers. It also reports that combined Pten loss and Pik3ca activation drove progression in a mouse model, but does not establish that loss of a tumor suppressor and oncogene activation are required for tumor progression generally, or that PIK3R1 mutations serve that activating role. (LLM, conf=0.87)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931 · see citing works
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · see citing works
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784 · see citing works
EMT: 2016
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492 · see citing works
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338 · see citing works
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Yang, W., Lum, A. M., Senz, J., Boyd, N., Pike, J. A., Anglesio, M. S., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 992 · see citing works
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 989 · see citing works
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
Stelloo, E., Nout, R. A., Osse, E. M., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 856 · see citing works
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan, V. W., Yang, H., Pike, M. C., McCann, S. E., Yu, H., Xiang, Y., Wolk, A., Wentzensen, N., Weiss, N. S., Webb, P. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.2596 · Cited by 830 · see citing works
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829 · see citing works
Milestones of Lynch syndrome: 1895–2015
Lynch, H. T., Snyder, C., Shaw, T. G., Heinen, C. D., & Hitchins, M. P. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3878 · Cited by 812 · see citing works
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
Kommoss, S., McConechy, M. K., Kommoss, F. K. F., Leung, S. C. Y., Bunz, A.-K., Magrill, J., Britton, H. M., Kommoss, F. K. F., Grevenkamp, F., Karnezis, A. N., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy058 · Cited by 791 · see citing works
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Massard, C., Michiels, S., Ferté, C., Deley, M. L., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E. E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783 · see citing works
International patterns and trends in endometrial cancer incidence, 1978-2013.
Lortet-Tieulent, J., Ferlay, J., Bray, F., & Jemal, A. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx214 · Cited by 760 · see citing works
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S. J., Stover, E. H., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 687 · see citing works
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 630 · see citing works
Cancer-associated mutations in endometriosis without cancer
Anglesio, M. S., Papadopoulos, N., Ayhan, A., Nazeran, T. M., Noë, M., Horlings, H. M., Lum, A., Jones, S., Senz, J., Seckin, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614814 · Cited by 628 · see citing works
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Berger, A. C., Korkut, A., Kanchi, R. S., Hegde, A. M., Lenoir, W. F., Liu, W., Liu, Y., Fan, H., Shen, H., Ravikumar, V., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.014 · Cited by 606 · see citing works
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A. M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 538 · see citing works
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Fader, A. N., Roque, D. M., Siegel, E. R., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L. J., O’Malley, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5966 · Cited by 518 · see citing works
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Ott, P. A., Bang, Y., Berton-Rigaud, D., Élez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I. J., Mehnert, J. M., Aung, K. L., Lopez, J. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5952 · Cited by 509 · see citing works
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative.
Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Nijman, H. W., Leary, A., Edmondson, R. J., Powell, M. E., Crosbie, E. J., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.43 · Cited by 486 · see citing works
Indexed Pain Journals
(U.S.), N. L. O. M. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 474 · see citing works
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke‐Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 471 · see citing works
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 467 · see citing works
WRN helicase is a synthetic lethal target in microsatellite unstable cancers
Chan, E. M., Shibue, T., McFarland, J. M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1102-x · Cited by 458 · see citing works
Integrated Molecular Characterization of Uterine Carcinosarcoma
Cherniack, A. D., Shen, H., Walter, V., Stewart, C., Murray, B. A., Bowlby, R., Hu, X., Ling, S., Soslow, R. A., Broaddus, R. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.010 · Cited by 435 · see citing works
Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women
Clarke, M. A., Long, B. J., Del Mar Morillo, A., Arbyn, M., Bakkum-Gamez, J. N., & Wentzensen, N. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.2820 · Cited by 426 · see citing works
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424 · see citing works
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes
Gallo, M. L., O’Hara, A. J., Rudd, M. L., Urick, M. E., Hansen, N. F., O’Neil, N. J., Price, J. C., Zhang, S., England, B. M., Godwin, A. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2455 · Cited by 418 · see citing works
Self-citation
Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium
Suda, K., Nakaoka, H., Yoshihara, K., Ishiguro, T., Tamura, R., Mori, Y., Yamawaki, K., Adachi, S., Takahashi, T., Kase, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.037 · Cited by 414 · see citing works
Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388 · see citing works
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, J., Hirshfield, K. M., Damare, S., Lane, K., Sokol, L. O., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 373 · see citing works
Cancer of the corpus uteri
Amant, F. C., Mirza, M. R., Koskas, M., & Creutzberg, C. L. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12612 · Cited by 357 · see citing works
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
Schwaederle, M. C., Zhao, M. M., Lee, J. J., Lazar, V., Leyland-Jones, B. R., Schilsky, R. L., Mendelsohn, J. M., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2129 · Cited by 349 · see citing works
p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.
Tashiro, H., Isacson, C., Levine, R. L., Kurman, R. J., Cho, K. R., & Hedrick, L. (1997) · Europe PMC (PubMed Central) · Cited by 345 · see citing works
p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis
Sherman, M. E., Bur, M. E., & Kurman, R. J. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90204-x · Cited by 342 · see citing works
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
Church, D. N., Stelloo, E., Nout, R. A., Valtcheva, N., Depreeuw, J., ter Haar, N. T., Noske, A., Amant, F. C., Tomlinson, I. P. M., Wild, P. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju402 · Cited by 334 · see citing works
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327 · see citing works
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
Kurnit, K. C., Kim, G. N., Fellman, B. M., Urbauer, D. L., Mills, G. B., Zhang, W., & Broaddus, R. R. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.15 · Cited by 325 · see citing works
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
Zhao, S., Choi, M., Overton, J. D., Bellone, S., Roque, D. M., Cocco, E., Guzzo, F., English, D. P.-G., Varughese, J., Gasparrini, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222577110 · Cited by 321 · see citing works
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 320 · see citing works
Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists
Soslow, R. A., Tornos, C. S., Park, K. J., Malpica, A. L., Matías‐Guiu, X., Oliva, E., Parkash, V., Carlson, J. W., McCluggage, W. G., & Gilks, C. B. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000518 · Cited by 317 · see citing works
Minimal functional driver gene heterogeneity among untreated metastases
Reiter, J. G., Makohon-Moore, A. P., Gerold, J. M., Heyde, A., Attiyeh, M. A., Kohutek, Z. A., Tokheim, C. J., Brown, A., DeBlasio, R. M., Niyazov, J., et al. (2018) · Science · doi:10.1126/science.aat7171 · Cited by 310 · see citing works
Cancer of the corpus uteri
Amant, F. C., Mirza, M. R., & Creutzberg, C. L. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60024-1 · Cited by 309 · see citing works
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C. U., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301 · see citing works
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers
Clarke, M. A., Devesa, S. S., Harvey, S. V., & Wentzensen, N. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00151 · Cited by 301 · see citing works
PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma.
Levine, R. L., Cargile, C. B., Blazes, M. S., van Rees, B. P., Kurman, R. J., & Ellenson, L. H. (1998) · PubMed · Cited by 290 · see citing works
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
McConechy, M. K., Ding, J., Senz, J., Yang, W., Melnyk, N., Tone, A. A., Prentice, L., Wiegand, K. C., McAlpine, J. N., Shah, S. P., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.107 · Cited by 287 · see citing works
Factors associated with Type I and Type II endometrial cancer
Felix, A. S., Weissfeld, J. L., Stone, R. A., Bowser, R. P., Chivukula, M., Edwards, R. P., & Linkov, F. Y. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9612-8 · Cited by 285 · see citing works
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
for the PORTEC Study Group, Wortman, B. G., Creutzberg, C. L., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Mens, J. W., Slot, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0310-8 · Cited by 284 · see citing works
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N. C., Joshua, A. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0364-2 · Cited by 276 · see citing works
Emerging therapeutic targets in endometrial cancer
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.216 · Cited by 270 · see citing works
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Dedes, K. J., Wetterskog, D., Mendes‐Pereira, A. M., Natrajan, R., Lambros, M. B. K., Geyer, F. C., Vatcheva, R., Savage, K., Mackay, A. G., Lord, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001538 · Cited by 253 · see citing works
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses
Kuhn, E., Wu, R., Guan, B., Wu, G., Zhang, J., Wang, Y., Song, L., Yuan, X., Wei, L., Roden, R. B. S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs345 · Cited by 249 · see citing works
Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers
Wang, Y., Li, L., Douville, C. B., Cohen, J. D., Yen, T., Kinde, I., Sundfelt, K., Kjær, S. K., Hruban, R. H., Shih, I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap8793 · Cited by 245 · see citing works
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Jankú, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D. D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 238 · see citing works
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Urick, M. E., Rudd, M. L., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0549 · Cited by 230 · see citing works
Self-citation
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition
Zhao, S., Bellone, S., Lopez, S., Thakral, D., Schwab, C. L., English, D. P.-G., Black, J., Cocco, E., Choi, J., Zammataro, L. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614120113 · Cited by 230 · see citing works
The genetic landscape of endometrial clear cell carcinomas
DeLair, D. F., Burke, K. A., Selenica, P., Lim, R. S., Scott, S. N., Middha, S., Mohanty, A. S., Cheng, D. T., Berger, M. F., Soslow, R. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4947 · Cited by 229 · see citing works
Conditional Loss of Uterine Pten Unfailingly and Rapidly Induces Endometrial Cancer in Mice
Daikoku, T., Hirota, Y., Tranguch, S. L., Joshi, A. R., DeMayo, F. J., Lydon, J. P., Ellenson, L. H., & Dey, S. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1274 · Cited by 225 · see citing works
A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
Rudd, M. L., Price, J. C., Fogoros, S. K., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0540 · Cited by 222 · see citing works
Self-citation
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
Hussein, Y. R., Weigelt, B., Levine, D. A., Schoolmeester, J. K., Dao, L. N., Balzer, B. L., Liles, G. B., Karlan, B. Y., Köbel, M., Lee, C., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.143 · Cited by 220 · see citing works
Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
Brinton, L. A., Felix, A. S., McMeekin, D. S., Creasman, W. T., Sherman, M. E., Mutch, D. G., Cohn, D. E., Walker, J. L., Moore, R. G., Downs, L. S., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.02.023 · Cited by 216 · see citing works
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
McMeekin, D. S., Tritchler, D., Cohn, D. E., Mutch, D. G., Lankes, H. A., Geller, M. A., Powell, M. A., Backes, F. J., Landrum, L. M., Zaino, R. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8722 · Cited by 210 · see citing works
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis
Gibson, W. J., Høivik, E. A., Halle, M. K., Taylor-Weiner, A. N., Cherniack, A. D., Berg, A., Holst, F., Zack, T. I., Werner, H. M. J., Staby, K. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3602 · Cited by 208 · see citing works
New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care
Talhouk, A., & McAlpine, J. N. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0035-4 · Cited by 208 · see citing works
Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type
Zighelboim, I., Goodfellow, P. J., Gao, F., Gibb, R. K., Powell, M. A., Rader, J. S., & Mutch, D. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2107 · Cited by 202 · see citing works
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E. S., Alva, A. S., Janeway, K. A., Stella, P. J., Voest, E. E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 194 · see citing works
Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada, H., Enomoto, T., Fujita, M., Yoshino, K., Nakashima, R., Kurachi, H., Haba, T., Wakasa, K., Shroyer, K. R., Tsujimoto, M., et al. (1997) · PubMed · Cited by 193 · see citing works
Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
McConechy, M. K., Talhouk, A., Leung, S. C. Y., Chiu, D. S., Yang, W., Senz, J., Reha-Krantz, L. J., Lee, C., Huntsman, D. D., Gilks, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2233 · Cited by 192 · see citing works
PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
Oda, K., Okada, J., Timmerman, L., Rodriguez‐Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0755 · Cited by 189 · see citing works
FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
Byron, S. A., Gartside, M. G., Powell, M. A., Wellens, C. L., Gao, F., Mutch, D. G., Goodfellow, P. J., & Pollock, P. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030801 · Cited by 187 · see citing works
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
Jardim, D. L. F., Schwaederle, M. C., Wei, C., Lee, J. J., Hong, D. S., Eggermont, A., Schilsky, R. L., Mendelsohn, J. M., Lazar, V., & Kurzrock, R. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv253 · Cited by 186 · see citing works
POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium
Meng, B., Hoang, L. N., McIntyre, J. B., Duggan, M. A., Nelson, G. S., Lee, C., & Köbel, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.05.006 · Cited by 182 · see citing works
Polymerase ɛ ( POLE ) mutations in endometrial cancer: Clinical outcomes and implications for L ynch syndrome testing
Billingsley, C. C., Cohn, D. E., Mutch, D. G., Stephens, J. A., Suarez, A. A., & Goodfellow, P. J. (2014) · Cancer · doi:10.1002/cncr.29046 · Cited by 174 · see citing works
Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
Wortman, B. G., Bosse, T., Nout, R. A., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Westerveld, H. G., van den Berg, H., Slot, A., Winter, K. A. J. D., Verhoeven-Adema, K. W., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.020 · Cited by 168 · see citing works
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes
Jones, S., Stransky, N., McCord, C. L., Cerami, E. G., Lagowski, J. P., Kelly, D. D., Angiuoli, S. V., Sausen, M., Kann, L. M., Shukla, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6006 · Cited by 167 · see citing works
Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Talhouk, A., Derocher, H., Schmidt, P., Leung, S. C. Y., Milne, K., Gilks, C. B., Anglesio, M. S., Nelson, B. H., & McAlpine, J. N. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3241 · Cited by 160 · see citing works
A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group.
Gruber, S., & Thompson, W. D. (1996) · PubMed · Cited by 153 · see citing works
Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.
Sherman, M. E., Sturgeon, S. R., Brinton, L. A., Potischman, N. A., Kurman, R. J., Berman, M. L., Mortel, R., Twiggs, L. B., Barrett, R. J., & Wilbanks, G. D. (1997) · PubMed · Cited by 152 · see citing works
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
Lieb, S., Blaha-Ostermann, S., Kamper, E., Rippka, J., Schwarz, C., Ehrenhöfer-Wölfer, K., Schlattl, A., Wernitznig, A., Lipp, J., Nagasaka, K., et al. (2019) · eLife · doi:10.7554/elife.43333 · Cited by 151 · see citing works
Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States
Freedman, A. N., Klabunde, C. N., Wiant, K. F., Enewold, L., Gray, S. W., Filipski, K. K., Keating, N. L., Leonard, D. G. B., Lively, T., McNeel, T. S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00169 · Cited by 151 · see citing works
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Soumerai, T. E., Donoghue, M. T. A., Bandlamudi, C., Srinivasan, P., Chang, M. T., Zamarin, D., Cadoo, K. A., Grisham, R. N., O'Cearbhaill, R. E., Tew, W. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0412 · Cited by 145 · see citing works
Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability
Kategaya, L., Perumal, S. K., Hager, J. H., & Belmont, L. D. (2019) · iScience · doi:10.1016/j.isci.2019.02.006 · Cited by 144 · see citing works
Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis
Jin, Z., Ogata, S., Tamura, G., Katayama, Y., Fukase, M., 矢島, 美., & Motoyama, T. (2003) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000092134.88121.56 · Cited by 136 · see citing works
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
Eggink, F. A., van Gool, I. C., Leary, A. F., Pollock, P. M., Crosbie, E. J., Mileshkin, L., Jordanova, E. S., Adam, J., Freeman-Mills, L., Church, D. N., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1264565 · Cited by 128 · see citing works
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
Vanderstraeten, A., Luyten, C., Verbist, G., Tuyaerts, S., & Amant, F. C. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1537-8 · Cited by 127 · see citing works
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Cosgrove, C. M., Cohn, D. E., Hampel, H., Frankel, W. L., Jones, D. M., McElroy, J. P., Suarez, A. A., Zhao, W., Chen, W., Salani, R., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.003 · Cited by 126 · see citing works
Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline PTEN Mutations
Ngeow, J. Y. Y., Stanuch, K., Mester, J. L., Barnholtz‐Sloan, J. S., & Eng, C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6656 · Cited by 125 · see citing works
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
Bian, X., Gao, J., Luo, F., Rui, C., Zheng, T., Wang, D., Wang, Y., Roberts, T. M., Liu, P., Zhao, J. J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.326 · Cited by 124 · see citing works
Recurrent <i>PPP2R1A</i> Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth
Haesen, D., Abbasi Asbagh, L., Derua, R., Hubert, A., Schrauwen, S., Hoorne, Y., Amant, F., Waelkens, E., Sablina, A., & Janssens, V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3342 · Cited by 124 · see citing works
Methylated DNA collected by tampons: a new tool to detect endometrial cancer.
Fiegl, H., Gattringer, C., Widschwendter, A., Schneitter, A., Ramoni, A., Sarlay, D., Gaugg, I., Goebel, G., Müller, H. M., Mueller-Holzner, E., et al. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.882.13.5 · Cited by 123 · see citing works
Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma
Britton, H. M., Huang, L., Lum, A. M., Leung, S. C. Y., Shum, K., Kale, M., Burleigh, A., Senz, J., Yang, W., McConechy, M. M., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.03.098 · Cited by 115 · see citing works
Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
Maritschnegg, E., Wang, Y., Pecha, N., Horvat, R., Nieuwenhuysen, E. V., Vergote, I. B., Heitz, F., Sehouli, J., Kinde, I., Diaz, L. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.3083 · Cited by 114 · see citing works
Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.
Bakkum-Gamez, J. N., Wentzensen, N., Maurer, M. J., Hawthorne, K. M., Voss, J. S., Kroneman, T. N., Famuyide, A. O., Clayton, A. C., Halling, K. C., Kerr, S. E., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.01.552 · Cited by 107 · see citing works
In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas
McConechy, M. K., Hoang, L. N., Chui, M. H., Senz, J., Yang, W., Rozenberg, N., Mackenzie, R., McAlpine, J. N., Huntsman, D. D., Clarke, B. A., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.18 · Cited by 104 · see citing works
Endometrial Cancer Risk Factors by 2 Main Histologic Subtypes
Yang, H., Wentzensen, N., Trabert, B. L., Gierach, G. L., Felix, A. S., Gunter, M. J., Hollenbeck, A. R., Park, Y., Sherman, M. E., & Brinton, L. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws200 · Cited by 102 · see citing works
Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study
Nair, N., Camacho‐Vanegas, O., Rykunov, D., Dashkoff, M., Camacho, S. C., Schumacher, C. A., Irish, J. C., Harkins, T. T., Freeman, E., Garcia, I., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002206 · Cited by 100 · see citing works
Targeted mutation analysis of endometrial clear cell carcinoma
Hoang, L. N., McConechy, M. K., Meng, B., McIntyre, J. B., Ewanowich, C. A., Gilks, C. B., Huntsman, D. D., Köbel, M., & Lee, C. (2014) · Histopathology · doi:10.1111/his.12581 · Cited by 96 · see citing works
Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression
Ashley, C. W., Paula, A. D. C., Kumar, R., Mandelker, D. L., Pei, X., Riaz, N., Reis-Filho, J. S., & Weigelt, B. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.032 · Cited by 94 · see citing works
Molecular characterization of uterine clear cell carcinoma
An, H., Logani, S., Isacson, C., & Ellenson, L. H. (2004) · Modern Pathology · doi:10.1038/modpathol.3800057 · Cited by 94 · see citing works
High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
Stelloo, E., Nout, R. A., Naves, L. C. L. M., ter Haar, N. T., Creutzberg, C. L., Smit, V. T. H. B. M., & Bosse, T. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.012 · Cited by 90 · see citing works
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone, S., Bignotti, E., Lonardi, S., Ferrari, F., Centritto, F., Masserdotti, A., Pettinella, F., Black, J., Menderes, G., Altwerger, G. H., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.023 · Cited by 84 · see citing works
Synthetically lethal nanoparticles for treatment of endometrial cancer
Ebeid, K., Meng, X., Thiel, K. W., Do, A., Geary, S. M., Morris, A. S., Pham, E. L., Wongrakpanich, A., Chhonker, Y. S., Murry, D. J., et al. (2017) · Nature Nanotechnology · doi:10.1038/s41565-017-0009-7 · Cited by 82 · see citing works
ARID1A Is Essential for Endometrial Function during Early Pregnancy
Kim, T. H., Yoo, J., Wang, Z., Lydon, J. P., Khatri, S., Hawkins, S. M., Leach, R. E., Fazleabas, A. T., Young, S. L., Lessey, B. A., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005537 · Cited by 77 · see citing works
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients
Bellone, S., Centritto, F., Black, J., Schwab, C. L., English, D. P.-G., Cocco, E., Lopez, S., Bonazzoli, E., Predolini, F., Ferrari, F., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.027 · Cited by 76 · see citing works
Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma
Kuhn, E., Bahadirli-Talbott, A., & Shih, I. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.209 · Cited by 75 · see citing works
Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing
Gallo, M. L., Rudd, M. L., Urick, M. E., Hansen, N. F., Zhang, S., Program, N. C. S., Lozy, F., Sgroi, D. C., Vidal, A., Matías‐Guiu, X., et al. (2017) · Cancer · doi:10.1002/cncr.30745 · Cited by 75 · see citing works
Self-citation
Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
van Gool, I. C., Rayner, E., Osse, E. M., Nout, R. A., Creutzberg, C. L., Tomlinson, I. P. M., Church, D. N., Smit, V. T. H. B. M., de Wind, N., Bosse, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0266 · Cited by 74 · see citing works
Effects of nitric oxide on the adhesion of human melanocytes to extracellular matrix components
Ivanova, K., Poole, I. C. L., Gerzer, R., Westerhof, W., & Das, P. K. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199712)183:4 · Cited by 73 · see citing works
DNA Mismatch Repair Deficiency Accelerates Endometrial Tumorigenesis in Pten Heterozygous Mice
Wang, H., Douglas, W., Lia, M., Edelmann, W., Kucherlapati, R., Podsypanina, K., Parsons, R. E., & Ellenson, L. H. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62573-4 · Cited by 69 · see citing works
p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans
Wild, P. J., Ikenberg, K., Fuchs, T. J., Rechsteiner, M., Georgiev, S., Fankhauser, N., Noske, A., Roessle, M., Caduff, R. F., Dellas, A., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101063 · Cited by 66 · see citing works
Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040.
Gaber, C., Meza, R., Ruterbusch, J. J., & Cote, M. L. (2017) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-016-0292-2 · Cited by 66 · see citing works
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
Miyasaka, A., Oda, K., Ikeda, Y., Wada‐Hiraike, O., Kashiyama, T., Enomoto, A., Hosoya, N., Koso, T., Fukuda, T., Inaba, K., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-179 · Cited by 65 · see citing works
Expression profiles of carcinosarcoma of the uterine corpus—are these similar to carcinoma or sarcoma?
Chiyoda, T., Tsuda, H., Tanaka, H., Kataoka, F., Nomura, H., Nishimura, S., Takano, M., Susumu, N., Saya, H., & Aoki, D. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20947 · Cited by 65 · see citing works
Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis
Guo, S. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12221 · Cited by 58 · see citing works
Endometrial Carcinomas With Clear Cells
Han, G., Soslow, R. A., Wethington, S. L., Levine, D. A., Bogomolniy, F., Clement, P. B., Köbel, M., Gilks, C. B., & DeLair, D. F. (2015) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000162 · Cited by 56 · see citing works
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Auguste, A., Genestie, C., de Bruyn, M., Adam, J., Formal, A. L., Drusch, F., Pautier, P., Crosbie, E. J., MacKay, H. J., Kitchener, H. C., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0055-1 · Cited by 56 · see citing works
Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia
Kipp, B. R., Medeiros, F., Campion, M. B., Distad, T. J., Peterson, L. M., Keeney, G. L., Halling, K. C., & Clayton, A. C. (2008) · Cancer · doi:10.1002/cncr.23636 · Cited by 56 · see citing works
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Meng, X., Bi, J., Li, Y., Yang, S., Zhang, Y., Li, M., Liu, H., Li, Y., McDonald, M. E., Thiel, K. W., et al. (2018) · Cancers · doi:10.3390/cancers10050149 · Cited by 53 · see citing works
Emergence, Involution, and Progression to Carcinoma of Mutant Clones in Normal Endometrial Tissues
Mutter, G. L., Monte, N. M., Neuberg, D. S., Ferenczy, A. S., & Eng, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0108 · Cited by 52 · see citing works
β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers
Myers, A. P., Barry, W. T., Hirsch, M. S., Matulonis, U. A., & Lee, L. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.010 · Cited by 51 · see citing works
Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers
Mota, A., Colás, E., García‐Sanz, P., Campoy, I., Rojo‐Sebastián, A., Gatius, S., García, Á., Chiva, L. M., Alonso, S., Gil‐Moreno, A., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.143 · Cited by 51 · see citing works
Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).
Fleming, G. F., Emens, L. A., Eder, J. P., Hamilton, E. P., Liu, J. F., Liu, B., Molinero, L. L., Fassò, M., O'Hear, C. E., & Braiteh, F. S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5585 · Cited by 51 · see citing works
Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors
Ayhan, A., Mao, T., Rahmanto, Y. S., Zeppernick, F. A., Ogawa, H., Wu, R., Wang, T., & Shih, I. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.22 · Cited by 51 · see citing works
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Jeske, Y. W. A., Ali, S., Byron, S. A., Gao, F., Mannel, R. S., Ghebre, R. G., DiSilvestro, P., Lele, S., Pearl, M. L., Schmidt, A. P., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.031 · Cited by 50 · see citing works
Endometrial cancer—targeted therapies myth or reality? Review of current targeted treatments
Lheureux, S., & Oza, A. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.016 · Cited by 49 · see citing works
Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma
Russo, M., Broach, J. R., Sheldon, K. E., Houser, K. R., Liu, D. J., Kesterson, J. P., Phaëton, R., Hossler, C., Hempel, N., Baker, M. J., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.07.003 · Cited by 41 · see citing works
Endometrial brush biopsy for the diagnosis of endometrial cancer.
Priore, G. D., Williams, R., Harbatkin, C. B., Ls, W., Mittal, K., & Gc, Y. (2001) · PubMed · Cited by 40 · see citing works
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study
Chawla, A., Jankú, F., Wheler, J. J., Miller, V. A., Ryan, J., Anhorn, R., Zhou, Z., & Signorovitch, J. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00074 · Cited by 39 · see citing works
The NCI-MATCH trial and precision medicine in gynecologic cancers
Barroilhet, L. M., & Matulonis, U. A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.01.008 · Cited by 39 · see citing works
Endocervical adenocarcinoma in situ: An analysis of cellular features
Biscotti, C. V., Gero, M. A., Toddy, S. M., Fischler, D. F., & Easley, K. A. (1997) · Diagnostic Cytopathology · doi:10.1002/(sici)1097-0339(199711)17:5 · Cited by 38 · see citing works
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53
Meng, X., Laidler, L. L., Kosmacek, E. A., Yang, S., Xiong, Z., Zhu, D., Wang, X., Dai, D. D., Zhang, Y., Wang, X., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.004 · Cited by 36 · see citing works
Palbociclib has antitumour effects on Pten‐deficient endometrial neoplasias
Santamaría, M. D., Mirantes, C., Eritja, N., Felip, I., Navaridas, R., Gatius, S., Santacana, M., Colás, E., Moiola, C. P., Schoenenberger-Arnaiz, J. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4896 · Cited by 35 · see citing works
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53
Meng, X., Dizon, D. S., Yang, S., Wang, X., Zhu, D., Thiel, K. W., & Leslie, K. K. (2013) · Obstetrics and Gynecology International · doi:10.1155/2013/828165 · Cited by 31 · see citing works
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas
Gallo, M. L., Rudd, M. L., Urick, M. E., Hansen, N. F., Merino, M. J., Mutch, D. G., Goodfellow, P. J., Mullikin, J. C., & Bell, D. W. (2017) · Cancer · doi:10.1002/cncr.30971 · Cited by 29 · see citing works
Self-citation
Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors
Ta, R. M., Hecht, J. L., & Lin, D. I. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.012 · Cited by 29 · see citing works
Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities
Terakawa, J., Serna, V. A., Taketo, M. M., Daikoku, T., Suarez, A. A., & Kurita, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814506116 · Cited by 28 · see citing works
Activated Mutant p110α Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion
Joshi, A. R., Miller, C. A., Baker, S. J., & Ellenson, L. H. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.12.019 · Cited by 27 · see citing works
Clinicopathologic Analysis of Matched Primary and Recurrent Endometrial Carcinoma
Soslow, R. A., Wethington, S. L., Cesari, M., Chiappetta, D., Olvera, N., Shia, J., & Levine, D. A. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318273591a · Cited by 27 · see citing works
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations
Shukla, S. A., Howitt, B. E., Wu, C. J., & Konstantinopoulos, P. A. (2016) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2016.12.009 · Cited by 26 · see citing works
Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978–2014
Faber, M. T., Frederiksen, K., Jensen, A., Aarslev, P. B., & Kjær, S. K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.015 · Cited by 23 · see citing works
Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma
de la Vega, L. L., Samaha, M. C., Hu, K. M., Bick, N. R., Siddiqui, J., Hovelson, D. H., Liu, C., Carter, C. S., Cho, K. R., Sciallis, A. P., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1178 · Cited by 22 · see citing works
Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?
Wong, A., & Ngeow, J. Y. Y. (2015) · BioMed Research International · doi:10.1155/2015/219012 · Cited by 22 · see citing works
Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms
Lin, M., Burkholder, K. A., Viswanathan, A. N., Neuberg, D. S., & Mutter, G. L. (2009) · Cancer · doi:10.1002/cncr.24218 · Cited by 22 · see citing works
Endometrial brush biopsy. An accurate outpatient method of detecting endometrial malignancy.
Wu, H. H., Casto, B. D., & Elsheikh, T. M. (2003) · PubMed · Cited by 19 · see citing works
Deletion of Arid1a in Reproductive Tract Mesenchymal Cells Reduces Fertility in Female Mice1
Wang, X., Khatri, S., Broaddus, R. R., Wang, Z., & Hawkins, S. M. (2016) · Biology of Reproduction · doi:10.1095/biolreprod.115.133637 · Cited by 16 · see citing works
In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI‐2 and dinaciclib
Urick, M. E., & Bell, D. W. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22867 · Cited by 15 · see citing works
Self-citation
Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsyPreprint
Martignetti, J. A., Pandya, D. S., Nagarsheth, N. P., Chen, Y., Camacho, O., Tomita, S. A., Brodman, M. L., Ascher‐Walsh, C., Kolev, V., Cohen, S., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a003269 · Cited by 13 · see citing works
Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
Musselman, K., Glynn, S. M., Mosquera, J. M., Elemento, O., Sboner, A., Beltran, H., & Holcomb, K. (2019) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2019.01.013 · Cited by 8 · see citing works
WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies.
Rodon, J. A., Soria, J., Berger, R., Miller, W. H., Lazar, V., Rubin, E., Tsimberidou, A. M., Saintigny, P., Ackerstein, A., Braña, I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12011 · Cited by 8 · see citing works
Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping
Bergstrom, C. P., Geest, K. D., O’Gara, R., Corless, C. L., & Morgan, T. K. (2016) · Reproductive Sciences · doi:10.1177/1933719116648213 · Cited by 6 · see citing works
Adenomatous Polyposis Syndromes: Polymerase Proofreading-Associated Polyposis
Palles, C., Latchford, A. R., & Valle, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-74259-5_8 · Cited by 5 · see citing works
Untitled work
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4

Flagged first, then by citations

Research works printed but not linked: 10

[48]Lax SF, Kendall B, Tashiro H, Slebos RJ & Hedrick L The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88, 814– 824 (2000). 10679651
[59]Abeln EC Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J. Pathol 183, 424– 431 (1997). 9496259
[61]Nieto MA, Huang RY, Jackson RA & Thiery JP EMT: 2016. Cell 166, 21– 45 (2016). 27368099
[84]Maksem J, Sager F & Bender R Endometrial collection and interpretation using the Tao brush and the CytoRich fixative system: a feasibility study. Diagn. Cytopathol 17, 339– 346 (1997). 9360046
[132]US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01775072. (2019). 28792816
[141]US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/. (2019). 28792816
[161]US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01876511. (2019). 28792816
[162]US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02178722. (2019). 28792816
[163]US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02054806. (2019). 28792816
[164]US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01375842. (2018). 28792816

Sorted by citations

The potential role of RNA N6-methyladenosine in Cancer progression
Wang, T., Kong, S., Tao, M., & Ju, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01204-7 · Cited by 1,018 · see citing works
Endometrial cancer
Makker, V., MacKay, H. J., Ray-Coquard, I. L., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 705 · see citing works
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases
Lu, Q., Zhu, Y., Deng, C., Liang, Z., Chen, J., Chen, Y., Wang, X., Liu, Y., Tian, Y., & Yang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01756-w · Cited by 360 · see citing works
The RING finger protein family in health and disease
Cai, C., Tang, Y., Zhai, J., & Zheng, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01152-2 · Cited by 194 · see citing works
Progesterone Actions and Resistance in Gynecological Disorders
MacLean, J. A., & Hayashi, K. (2022) · Cells · doi:10.3390/cells11040647 · Cited by 196 · see citing works
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity
Matsuzaki, S., Klar, M., Matsuzaki, S., Roman, L. D., Sood, A. K., & Matsuo, K. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.043 · Cited by 117 · see citing works
Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives
Terzić, M., Aimagambetova, G. N., Kunz, J., Bapayeva, G., Aitbayeva, B., Terzic, S., & Laganà, A. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179274 · Cited by 111 · see citing works
CD45RO-CD8+ T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ERβ/miR-765/PLP2/Notch axis
Zhou, W., Zhang, J., Xie, F., Wu, J., Ye, J., Wang, J., Wu, K., & Li, M. (2021) · Theranostics · doi:10.7150/thno.58337 · Cited by 107 · see citing works
Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection
Galant, N., Krawczyk, P. A., Monist, M. J., Obara, A., Gajek, Ł., Grenda, A., Nicoś, M., Kalinka‐Warzocha, E., & Milanowski, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115893 · Cited by 111 · see citing works
Genomic landscape of endometrial carcinomas of no specific molecular profile
Boroujeni, A. M., Nguyen, B., Vanderbilt, C., Ladanyi, M., Abu‐Rustum, N. R., Aghajanian, C. A., Ellenson, L. H., Weigelt, B., & Soslow, R. A. (2022) · Modern Pathology · doi:10.1038/s41379-022-01066-y · Cited by 98 · see citing works
Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers
Chimento, A., Luca, A. D., Avena, P., Amicis, F. D., Casaburi, I., Sirianni, R., & Pezzi, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031242 · Cited by 91 · see citing works
Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies
Yang, Y., Wu, S. F., & Bao, W. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14969 · Cited by 89 · see citing works
Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer
Gu, X., Shi, Y., Dong, M., Li, J., Yang, J., & Liu, Z. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04087-8 · Cited by 82 · see citing works
Current and Emerging Prognostic Biomarkers in Endometrial Cancer
Njoku, K., Barr, C. E., & Crosbie, E. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.890908 · Cited by 87 · see citing works
Recurrent Endometrial Cancer: Local and Systemic Treatment Options
Rütten, H., Verhoef, C. G., van Weelden, W. J., Smits, A., Dhanis, J., Ottevanger, N. P. B., & Pijnenborg, J. M. A. (2021) · Cancers · doi:10.3390/cancers13246275 · Cited by 81 · see citing works
Minimally invasive approaches for the early detection of endometrial cancer
Shen, Y., Yang, W., Liu, J., & Zhang, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01757-3 · Cited by 76 · see citing works
Current Approaches to the Management of Patients with Endometrial Cancer
Kalampokas, E., Giannis, G., Kalampokas, T., Papathanasiou, A.-A., Mitsopoulou, D., Tsironi, E. E., Triantafyllidou, O., Gurumurthy, M., Parkin, D. E., Cairns, M. R., et al. (2022) · Cancers · doi:10.3390/cancers14184500 · Cited by 74 · see citing works
Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview
Gullo, G., Etrusco, A., Cucinella, G., Perino, A., Chiàntera, V., Laganà, A. S., Tomaiuolo, R., Vitagliano, A., Giampaolino, P., Noventa, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111825 · Cited by 70 · see citing works
One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids
Geurts, M. H., Gandhi, S., Boretto, M. G., Akkerman, N., Derks, L. L. M., van Son, G., Celotti, M., Harshuk-Shabso, S., Peci, F., Begthel, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40701-3 · Cited by 66 · see citing works
PRMT3‐Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma
Wang, Y., Wang, C., Guan, X., Ma, Y., Zhang, S., Li, F., Yin, Y., Sun, Z., Chen, X., & Yin, H. (2023) · Advanced Science · doi:10.1002/advs.202303812 · Cited by 65 · see citing works
The Significance of Secreted Phosphoprotein 1 in Multiple Human Cancers
Wei, T., Bi, G., Bian, Y., Ruan, S., Yuan, G., Xie, H., Zhao, M., Shen, R., Zhu, Y., Wang, Q., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.565383 · Cited by 65 · see citing works
High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential
Wang, L., Zhang, J., Xia, M. H., Liu, C., Zu, X., & Zhong, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72952 · Cited by 63 · see citing works
The role of miRNAs in the pathogenesis and therapeutic resistance of endometrial cancer: a spotlight on the convergence of signaling pathways
Abdelmaksoud, N. M., El‐Mahdy, H. A., Ismail, A., Elsakka, E. G. E., El-Husseiny, A. A., Khidr, E. G., Ali, E. M., Rashed, M. H., El-Demerdash, F. E.-S., & Doghish, A. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154411 · Cited by 63 · see citing works
A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer
Yasin, H. K., Taylor, A. H., & Ayakannu, T. (2021) · Cancers · doi:10.3390/cancers13092149 · Cited by 63 · see citing works
Remodeling Tumor Microenvironment by Multifunctional Nanoassemblies for Enhanced Photodynamic Cancer Therapy
Liang, C., Zhang, X., Yang, M., Wang, W., Chen, P., & Dong, X. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00259 · Cited by 60 · see citing works
LncRNA–miRNA–mRNA regulatory axes in endometrial cancer: a comprehensive overview
Shetty, A., Venkatesh, T., Kabekkodu, S. P., Tsutsumi, R., & Suresh, P. S. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06423-5 · Cited by 60 · see citing works
Esculetin inhibits endometrial cancer proliferation and promotes apoptosis via hnRNPA1 to downregulate BCLXL and XIAP
Jiang, R., Su, G., Chen, X., Chen, S., Li, Q., Xie, B., & Zhao, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.039 · Cited by 59 · see citing works
The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
Pang, Y., Bai, G., Zhao, J., Wei, X., Li, R., Li, J., Hu, S., Peng, L., Liu, P., & Mao, H. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03545-x · Cited by 59 · see citing works
Mechanism investigation and experiment validation of capsaicin on uterine corpus endometrial carcinoma
Lin, Z., Sui, X., Jiao, W., Chen, C., Zhang, X., & Zhao, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.953874 · Cited by 57 · see citing works
Facts and Hopes in Immunotherapy of Endometrial Cancer
Marín‐Jiménez, J. A., García‐Mulero, S., Matías‐Guiu, X., & Piulats, J. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1564 · Cited by 54 · see citing works
Metabolic reprogramming and interventions in endometrial carcinoma
Li, J., Yang, H., Zhang, L., Zhang, S., & Dai, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114526 · Cited by 54 · see citing works
Regulatory mechanism of miR-20a-5p expression in Cancer
Huang, W., Wu, X., Xiang, S., Qiao, M., Cen, X. B., Pan, X., Huang, X., & Zhao, Z. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01005-5 · Cited by 53 · see citing works
Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer
Kojima, M., Sugimoto, K., Tanaka, M., Endo, Y., Kato, H., Honda, T., Furukawa, S., Nishiyama, H., Watanabe, T., Soeda, S., et al. (2020) · Cancers · doi:10.3390/cancers12102748 · Cited by 51 · see citing works
Tissue Infiltrating Immune Cells as Prognostic Biomarkers in Endometrial Cancer: A Meta-Analysis
Guo, F., Dong, Y., Tan, Q., Kong, J., & Yu, B. (2020) · Disease Markers · doi:10.1155/2020/1805764 · Cited by 49 · see citing works
WTAP facilitates progression of endometrial cancer via CAV‐1/NF‐κB axis
Li, Q., Wang, C., Dong, W., Su, Y., & Ma, Z. (2021) · Cell Biology International · doi:10.1002/cbin.11570 · Cited by 48 · see citing works
Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines
Hsin, I., Shen, H., Chang, H. H., Ko, J., & Wang, P.-H. (2021) · Cells · doi:10.3390/cells10112916 · Cited by 48 · see citing works
Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer
Dai, M., Yang, B., Chen, J., Liu, F., Zhou, Y., Zhou, Y., Xu, Q., Jiang, S., Zhao, S., Li, X., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.024 · Cited by 47 · see citing works
Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis
Reske, J. J., Wilson, M. R., Holladay, J., Siwicki, R. A., Skalski, H. J., Harkins, S. K., Adams, M., Risinger, J. I., Hostetter, G. H., Lin, K. Y., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009986 · Cited by 44 · see citing works
Exploring the mechanism and experimental verification of puerarin in the treatment of endometrial carcinoma based on network pharmacology and bioinformatics analysis
Lin, Z., Sui, X., Jiao, W., Wang, Y., & Zhao, J. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03623-z · Cited by 42 · see citing works
Autophagy Machinery as a Promising Therapeutic Target in Endometrial Cancer
Núñez-Olvera, S. I., Gallardo‐Rincón, D., Puente-Rivera, J., Salinas-Vera, Y. M., Marchat, L. A., Morales-Villegas, R., & López‐Camarillo, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01326 · Cited by 42 · see citing works
Aberrant Claudin-6–Adhesion Signaling Promotes Endometrial Cancer Progression via Estrogen Receptor α
Kojima, M., Sugimoto, K., Kobayashi, M., Ichikawa‐Tomikawa, N., Kashiwagi, K., Watanabe, T., Soeda, S., Fujimori, K., Chiba, H., Nishiyama, H., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0835 · Cited by 39 · see citing works
LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer
Zhan, L., Zhang, J., Zhang, J., Liu, X., Zhu, S., Shi, Y., He, Y., Wang, W., Fan, Y., Tang, Z., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.031 · Cited by 41 · see citing works
Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
Lv, M., Chen, P., Bai, M., Huang, Y., Li, L., Feng, Y., Liao, H., Zheng, W., Chen, X., & Zhang, Z. (2022) · Cancers · doi:10.3390/cancers14246210 · Cited by 40 · see citing works
Organoid Models of Human Endometrial Development and Disease
Hibaoui, Y., & Féki, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00084 · Cited by 40 · see citing works
Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs
Ren, F., Wang, L., Wang, Y., Wang, J., Wang, Y., Song, X., Zhang, G., Nie, F., & Lin, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06960-8 · Cited by 43 · see citing works
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer
Tang, W., Ramasamy, K., Pillai, S. M. A., Santhamma, B., Konda, S., Venkata, P. P., Blankenship, L. M., Liu, J., Liu, Z., Altwegg, K. A., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00603-z · Cited by 37 · see citing works
Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenols—The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer
Olcha, P., Winiarska‐Mieczan, A., Kwiecień, M., Nowakowski, Ł., Miturski, A., Semczuk, A., Kiczorowska, B., & Gałczyński, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126703 · Cited by 38 · see citing works
ARID1A mutations in cancer development: mechanism and therapy
Zhang, X., Zhang, Y., Zhao, J., Wu, Y., Zhang, N., & Shen, W. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad011 · Cited by 36 · see citing works
Methoxyeugenol regulates the p53/p21 pathway and suppresses human endometrial cancer cell proliferation
Costa, B. P., Nassr, M. T., Diz, F. M., Antunes, K. H., Antunes, G. L., Grün, L. K., Barbé‐Tuana, F. M., Nunes, F. B., Branchini, G., & de Oliveira, J. R. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113645 · Cited by 36 · see citing works
The Perspectives of Fertility Preservation in Women with Endometrial Cancer
Knez, J., Mahdawi, L. A., Takač, I., & Sobočan, M. (2021) · Cancers · doi:10.3390/cancers13040602 · Cited by 36 · see citing works
Mining TCGA Data for Key Biomarkers Related to Immune Microenvironment in Endometrial cancer by Immune Score and Weighted Correlation Network Analysis
Guo, C., Tang, Y., Zhang, Y., & Li, G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.645388 · Cited by 36 · see citing works
Immune checkpoint inhibitors in endometrial cancer
Gómez-Raposo, C., Salvador, M. M., Zamora, C. A., de Santiago, B. G., & Sáenz, E. C. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103306 · Cited by 36 · see citing works
Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
Rizzo, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133912 · Cited by 36 · see citing works
Hinokitiol Exhibits Antitumor Properties through Induction of ROS-Mediated Apoptosis and p53-Driven Cell-Cycle Arrest in Endometrial Cancer Cell Lines (Ishikawa, HEC-1A, KLE)
Chen, H.-Y., Cheng, W.-P., Chiang, Y., Hong, Y.-H., Ali, M. K., Huang, T., Wang, K.-L., Shieh, T., Chang, H., & Hsia, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158268 · Cited by 35 · see citing works
WTAP/IGF2BP3 mediated m6A modification of the EGR1/PTEN axis regulates the malignant phenotypes of endometrial cancer stem cells
Wang, B., Wang, Y., Wang, W., Wang, Z., Zhang, Y., Pan, X. L., Wen, X., Leng, H., Guo, J. H., & Ma, X. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03120-w · Cited by 35 · see citing works
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
Drakes, M. L., Czerlanis, C. M., & Stiff, P. J. (2020) · Cancers · doi:10.3390/cancers12113301 · Cited by 35 · see citing works
SEOM-GEICO clinical guidelines on endometrial cancer (2021)
Barretina-Ginesta, M.-P., Quindós, M., Alarcón, J., Esteban, C., Gaba, L., Gómez, C., Fidalgo, J. A. P., Romero, I., Santaballa, A., & Rubio-Pérez, M. J. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02799-7 · Cited by 34 · see citing works
A novel strategy for tumor therapy: targeted, PAA-functionalized nano-hydroxyapatite nanomedicine
Zhang, S., Ma, X., Sha, D., Qian, J., Yuan, Y., & Liu, C. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01603a · Cited by 34 · see citing works
Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT
Zhang, J., Zhou, L., Xiang, J., Jin, C., Li, M., & He, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107705 · Cited by 34 · see citing works
UPF1 contributes to the maintenance of endometrial cancer stem cell phenotype by stabilizing LINC00963
Chen, H., Ma, J., Kong, F., Song, N., Wang, C., & Ma, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04707-x · Cited by 33 · see citing works
Quercetin inhibits the progression of endometrial HEC-1-A cells by regulating ferroptosis—a preliminary study
Li, X., Zhu, Q., Ma, M., & Guo, H. (2022) · European journal of medical research · doi:10.1186/s40001-022-00934-2 · Cited by 33 · see citing works
A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth
Li, S., Ou, L., Zhang, Y., Shen, F., & Chen, Y.-G. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05682-7 · Cited by 32 · see citing works
Construction of Oxidative Stress-Related Genes Risk Model Predicts the Prognosis of Uterine Corpus Endometrial Cancer Patients
Liu, Q., Yu, M., & Zhang, T. (2022) · Cancers · doi:10.3390/cancers14225572 · Cited by 31 · see citing works
Circular RNAs: Novel biomarkers for cervical, ovarian and endometrial cancer (Review)
Shi, Y., He, R., Yu, Y., He, Y., Shao, K., Zhan, L., & Wei, B. (2020) · Oncology Reports · doi:10.3892/or.2020.7780 · Cited by 30 · see citing works
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer
Zhan, L., Zhang, J., Zhang, J., Liu, X., Guo, B., Chen, J.-H., Tang, Z., Wang, W., Wang, Q.-Y., Wei, B., et al. (2023) · Biomarker Research · doi:10.1186/s40364-023-00479-4 · Cited by 29 · see citing works
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records
Monk, B. J., Smith, G. B., Lima, J., Long, G. H., Alam, N., Nakamura, H., Meulendijks, D., Ghiorghiu, D. C., & Banerjee, S. N. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.12.008 · Cited by 29 · see citing works
An integrated autophagy-related gene signature predicts prognosis in human endometrial Cancer
Zhang, J., Wang, Z., Zhao, R., An, L., Zhou, X., Zhao, Y., & Wang, H. (2020) · BMC Cancer · doi:10.1186/s12885-020-07535-4 · Cited by 28 · see citing works
Leptin secreted by adipocytes promotes EMT transition and endometrial cancer progression via the JAK2/STAT3 signalling pathway
Shen, L., Zhang, C., Cui, K., Liang, X., Zhu, G., & Hong, L. (2023) · Adipocyte · doi:10.1080/21623945.2023.2293273 · Cited by 26 · see citing works
KIF4A promotes genomic stability and progression of endometrial cancer through regulation of TPX2 protein degradation
Zhang, J., An, L., 俞志誠, Zhao, R., Shi, R., Zhou, X., Wei, S., Zhang, T., Zhang, T., 冯地路, et al. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23487 · Cited by 26 · see citing works
Roles of estrogen receptor α in endometrial carcinoma (Review)
Ge, Y., Ni, X., Li, J., Ye, M., & Jin, X. (2023) · Oncology Letters · doi:10.3892/ol.2023.14117 · Cited by 28 · see citing works
Notch and Endometrial Cancer
Jonušienė, V., & Sasnauskienė, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_4 · Cited by 25 · see citing works
Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB
Cui, Y., Wu, H., Yang, L., Huang, T., Li, J., Gong, X., Li, L., Sun, X., Mao, F., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665832 · Cited by 25 · see citing works
Fatty Acid–Binding Protein 4 (FABP4) Suppresses Proliferation and Migration of Endometrial Cancer Cells via PI3K/Akt Pathway
Wu, Z., Jeong, J.-H., Ren, C., Yang, L., Ding, L., Li, F., Jiang, D., Zhu, Y., & Lu, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s311792 · Cited by 25 · see citing works
From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer
Molefi, T., Mabonga, L., Hull, R., Sebitloane, M., & Dlamini, Z. (2025) · Cancers · doi:10.3390/cancers17020320 · Cited by 24 · see citing works
Combining Clinicopathological Parameters and Molecular Indicators to Predict Lymph Node Metastasis in Endometrioid Type Endometrial Adenocarcinoma
Jiang, P., Huang, Y., Tu, Y., Li, N., Kong, W., Di, F., Jiang, S., Zhang, J., Yi, Q., & Yuan, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682925 · Cited by 24 · see citing works
Hypermethylated PCDHGB7 as a Biomarker for Early Detection of Endometrial Cancer in Endometrial Brush Samples and Cervical Scrapings
Yuan, J., Mao, Z., Qi, L., Xu, P., Wang, C., Xu, X., Zhou, Z., Zhang, T., Yu, W., Dong, S., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.774215 · Cited by 24 · see citing works
m6A mRNA methylation regulates the ERK/NF-κB/AKT signaling pathway through the PAPPA/IGFBP4 axis to promote proliferation and tumor formation in endometrial cancer
Ruan, P., Wang, S., Yang, C., Huang, X., Sun, P., & Tan, A. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09751-z · Cited by 24 · see citing works
CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma
Xue, S., Su, L., Ke, L.-N., & Huang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1077780 · Cited by 24 · see citing works
A Nomogram Model for Predicting Recurrence of Stage I–III Endometrial Cancer Based on Inflammation-Immunity-Nutrition Score (IINS) and Traditional Classical Predictors
Jiang, P., Wang, J., Gong, C., Yi, Q., Zhu, M., & Hu, Z. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s362166 · Cited by 23 · see citing works
Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment
Ribeiro-Santos, P., Vieira, C. M., Veloso, G. G. V., Giannecchini, G. V., Arenhardt, M. P., Gomes, L. M., Zanuncio, P. H. D. R., Brandão, F. S., & Nogueira‐Rodrigues, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147742 · Cited by 24 · see citing works
Amentoflavone promotes ferroptosis by regulating reactive oxygen species (ROS) /5’AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) to inhibit the malignant progression of endometrial carcinoma cells
Sun, Q., Peng, Z., Li, D., Liu, X., Ding, X., & Liu, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2079256 · Cited by 23 · see citing works
Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
Baiden-Amissah, R. E. M., Annibali, D., Tuyaerts, S., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13163988 · Cited by 22 · see citing works
Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives
Martín‐Sabroso, C., Lozza, I., Torres‐Suárez, A. I., & Fraguas‐Sánchez, A. I. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101705 · Cited by 22 · see citing works
SWI/SNF Antagonism of PRC2 Mediates Estrogen-Induced Progesterone Receptor Expression
Wilson, M. R., Reske, J. J., Koeman, J. M., Adams, M., Joshi, N., Fazleabas, A. T., & Chandler, R. L. (2022) · Cells · doi:10.3390/cells11061000 · Cited by 22 · see citing works
Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers
Zhang, Y., Peng, F., & Yu, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114016 · Cited by 22 · see citing works
Secreted frizzled-related proteins: A promising therapeutic target for cancer therapy through Wnt signaling inhibition
Zhang, W., Zhang, K., Ma, Y., Song, Y., Qi, T., Xiong, G., Zhang, Y., Kan, C., Zhang, J., Han, F., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115344 · Cited by 22 · see citing works
Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population
Kang, N., Zhang, X., Wang, Z., Dai, Y., Lu, S., Su, W., Gai, F., Zhu, C., Shen, D., & Wang, J. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155152 · Cited by 22 · see citing works
The Role of Hypoxia in Endometrial Cancer
Salinas-Vera, Y. M., Gallardo‐Rincón, D., Ruíz‐García, E., Silva-Cázares, M. B., de la Peña-Cruz, C. S., & López‐Camarillo, C. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210224130022 · Cited by 21 · see citing works
Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer
Choi, J. Y., Holowatyj, A. N., Du, M., Chen, Z., Wen, W., Schultz, N., Lipworth, L., & Guo, X. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00401 · Cited by 21 · see citing works
The Regulatory Role of Lipid Metabolism in Endometrial Cancer
Zhang, S., & Han, X. (2022) · Journal of Oncology · doi:10.1155/2022/6458877 · Cited by 20 · see citing works
Claudin‑9 is a novel prognostic biomarker for endometrial cancer
Endo, Y., Sugimoto, K., Kobayashi, M., Kobayashi, Y., Kojima, M., Furukawa, S., Soeda, S., Watanabe, T., Higashi, A. Y., Higashi, T., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5425 · Cited by 20 · see citing works
Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification
Pijnenborg, J. M. A., van Weelden, W. J., Reijnen, C., Xanthoulea, S., & Romano, A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00470 · Cited by 20 · see citing works
A novel risk score system of immune genes associated with prognosis in endometrial cancer
Zhou, H., Zhang, C., Li, H., Chen, L., & Cheng, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01317-5 · Cited by 20 · see citing works
Oncogenic circular RNA circ_0007534 contributes to paclitaxel resistance in endometrial cancer by sponging miR-625 and promoting ZEB2 expression
Yi, H., Han, Y., & Li, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.985470 · Cited by 19 · see citing works
Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer
Bian, X., Sun, C., Cheng, J., & Hong, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092241 · Cited by 19 · see citing works
Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis
Chen, Y., Han, L., & Zheng, A. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.11.013 · Cited by 19 · see citing works
The Exploration of Chemokines Importance in the Pathogenesis and Development of Endometrial Cancer
Dobroch, J., Bojczuk, K., Kołakowski, A., Baczewska, M., & Knapp, P. (2022) · Molecules · doi:10.3390/molecules27072041 · Cited by 18 · see citing works
Synaptotagmin-like protein 1 is a potential diagnostic and prognostic biomarker in endometrial cancer based on bioinformatics and experiments
Meijuan, C., Xu, M. J., Fang, L., & Wang, Q. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01097-2 · Cited by 18 · see citing works
LncRNA FIRRE regulated endometrial cancer radiotherapy sensitivity via the miR-199b-5p/SIRT1/BECN1 axis-mediated autophagy
Cai, J., Wang, R., Chen, Y., Zhang, C., Fu, L., & Fan, C. (2023) · Genomics · doi:10.1016/j.ygeno.2023.110750 · Cited by 18 · see citing works
The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway
Tang, M., Yin, S., Zeng, H., Huang, A., Huang, Y., Hu, Z., Shah, A. R., Zhang, S., Li, H., & Chen, G. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06418-3 · Cited by 19 · see citing works

Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
Baiden-Amissah, R. E. M., Annibali, D., Tuyaerts, S., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13163988 · Cited by 22 · see citing works
Molecular characteristics of endometrial cancer: entering the era of precision medicine
Rybin, A., Kuznetsova, O., & Zamyshlyak, V. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.87.70267
Molecular characterization of endometrial cancer and therapeutic implications
Winterhoff, B. J. N., Thomaier, L., Mullany, S. A., & Powell, M. A. (2019) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000602 · Cited by 59 · see citing works
Analysis of the molecular profile of endometrial cancer depending on microsatelite instability
Tripac, I., Harasani, K., Čelebić, A., Calleja‐Agius, J., STRATAN, V., Valeri, Ţ., & Sîtnic, V. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.109645 · Cited by 2 · see citing works
Molecular pathology of endometrial cancer: recent advances in classification, prognostication, and management
Alfaraidi, M., Huvila, J. K., & Gilks, C. B. (2024) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2024.06.003 · Cited by 2 · see citing works

Authors: Urick, M. E., & Bell, D. W.
Affiliations: National Institutes of Health (US)
Corresponding author: Bell, Daphne W.
ORCID: Urick, Mary Ellen
Bell, Daphne W.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2019-08-06
Volume: 19
Issue: 9
Pages: 510-521
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/s41568-019-0177-x
PMC: PMC7446243
OpenAlex: W2965204233
Cited by: 405
References: 157
Citations by year: 2026: 19 · 2025: 57 · 2024: 58 · 2023: 70 · 2022: 101 · 2021: 66 · 2020: 32 · 2019: 2
FWCI: 8.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 HG999999)
National Human Genome Research Institute (Z01HG200338, ZIAHG200379, ZIAHG200338)
Topics: Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords: endometrial cancer, molecular subtyping, molecular targets, targeted therapy, early detection, risk stratification, endometrioid carcinoma, serous carcinoma, clear cell carcinoma, histological subtypes, prognosis
MeSH terms: Animals, Carcinoma, Female, Humans, Immunotherapy, Mutation, Prognosis, Risk, Sarcoma, Biomarkers, Tumor, Endometrial Neoplasms, Risk Assessment, Proteomics, Mice, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical actionability of molecular targets in endometrial cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks